Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GlycanAge

Explore full profile

Offers an at-home biological age testing kit that analyzes blood samples and provides personalized wellness advice to increase longevity

Newcastle upon Tyne, United KingdomFounded 2016Biotech & Life Sciences
Valuation $50–100M Last recorded · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for GlycanAge and the history behind them.

About GlycanAge

GlycanAge is a biotechnology company specializing in biological age testing through advanced glycomic analysis. The core product is an at-home test kit that measures biological age by analyzing glycosylation patterns on Immunoglobulin G (IgG) proteins in a small blood sample. These glycan patterns are sensitive indicators of chronic inflammation and are influenced by lifestyle, providing a more dynamic and actionable measure of aging than genetic or epigenetic clocks. The test is based on over 30 years of scientific research and more than 200,000 samples, with findings regularly published in leading medical journals.

The process is straightforward: users collect a few drops of blood using the provided kit, send it to the lab, and receive a detailed report within three weeks. Each test includes a complimentary consultation with a specialist, who interprets the results and offers personalized lifestyle recommendations to optimize health and potentially reduce biological age. GlycanAge’s approach is unique in its responsiveness to lifestyle changes, making it a valuable tool for individuals seeking to track the effectiveness of interventions such as diet, exercise, or menopause management.

GlycanAge’s technology is underpinned by a robust scientific foundation and is used by both health enthusiasts and researchers. The company is also expanding its reach into disease diagnostics, leveraging glycan biomarkers for early detection and precision medicine. Its recent funding and collaborations highlight its role as a pioneer in the field of preventative healthcare and longevity science.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Newcastle upon Tyne, United Kingdom
Employees
49
Open positions
None listed
Dealroom signal
88.6/100
Industry
Health, Wellness Beauty
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Personal Health, Testing, Biotechnology, Health and Wellness, Biomarkers, Precision Medicine, Tech for Patients, EIT Health
Business model
Manufacturing
Client focus
b2b

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Dec 2025 $8.7M $35M Impetus Capital · Vesna VC · South Central Ventures · Guinness Ventures ↗
SERIES A✓Equity / VC Nov 2025 $1.6M $6.3M Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

GlycanAge website traffic

Latest recorded traffic for GlycanAge is 37K monthly website visits, up 23.3% over the last three months. GlycanAge's team grew 16.7% over the past year.

Latest monthly visits37K 3-month web change+23.3% 1-year team growth+16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

24 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed8 investors entered at this stage

  • Tim Marbach
  • Pareto Holdings
  • Inaki Berenguer
  • Maud Pasturaud
  • SQ Capital
  • Hub71
  • LAUNCHub Ventures
  • Kadmos Capital

Series B and later7 investors entered at this stage

  • Fifth Quarter Ventures
  • Impetus Capital
  • Vesna VC
  • South Central Ventures
  • Guinness Ventures
  • BrightCap Ventures
  • Lightfield Equity

Other known investors9 additional known investors

  • EIT Health
  • AI Visionaries Incubator by Female Foundry and Google Cloud
  • Edward Lando
  • Exceptional Ventures
  • Jon Oringer
  • Nadav Ben-Chanoch
  • TEAM SY
  • TS Ventures Fund
  • Unit Ventures
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
10 countries with
team presence
🇭🇷 Croatia37.2%
🇬🇧 United Kingdom23.3%
🇧🇬 Bulgaria13.9%
🇺🇸 United States9.3%
🇲🇰 North Macedonia4.7%
Top 5 of 10 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GlycanAge on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GlycanAge’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.